Middle East & Africa Hyperpigmentation Disorder Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type, Condition, and End User

Description

List of Tables

The Middle East & Africa hyperpigmentation disorder treatment market was valued at US$ 530.30 million in 2022 and is expected to reach US$ 894.55 million by 2030; it is estimated to register a CAGR of 6.8% from 2022 to 2030.

Novel Products Based on PATH-3 Technology Bolster Middle East & Africa Hyperpigmentation Disorder Treatment Market

ALASTIN has formulated the PATH-3 technology and validated it through gene expression and cellular models to counteract the pigmentary pathways. This technology helps prevent the recurrence of surface pigmentation and provides protection against future damage due to continued use. The PATH-3 technology also complements in-office treatments, including lasers, skin brightening treatments, and chemical peels. The lightweight, elegant, non-irritating serum used in PATH-3 is formulated without retinol or hydroquinone and is safe for long-term daily use. A novel topical product enabled by the PATH-3 technology has been proven effective and safe in treating facial dyschromia. In October 2022, Galderma launched ALASTIN Skincare A-LUMINATE BRIGHTENING SERUM based on PATH-3 Technology. The new product addition to the ALASTIN Skincare lineup is designed to help lower the appearance of surface hyperpigmentation without any irritating, harsh ingredients. Thus, novel products enabled by the PATH-3 technology are expected to emerge as new trends in the hyperpigmentation disorder treatment market during the forecast period.

Middle East & Africa Hyperpigmentation Disorder Treatment Market Overview

Israel, Iran, Iraq, Kuwait, Oman, Egypt, and Kenya are among the major contributors to the Rest of Middle East & Africa hyperpigmentation disorder treatment market. The diverse population in South Africa, with varying skin types and concerns, presents an opportunity for skincare providers to offer personalized solutions tailored to individual needs. This personalized approach, combined with increasing disposable income and a growing middle-class population, is driving the demand for effective hyperpigmentation treatments in the Rest of MEA. Overall, these factors are leading to the growth of the hyperpigmentation disorder treatment market in the region, with prospects for continued expansion in the future.

Middle East & Africa Hyperpigmentation Disorder Treatment Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Hyperpigmentation Disorder Treatment Market Segmentation

The Middle East & Africa hyperpigmentation disorder treatment market is categorized into treatment type, condition, end user, and country.

By treatment type, the Middle East & Africa hyperpigmentation disorder treatment market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held the largest share of the Middle East & Africa hyperpigmentation disorder treatment market share in 2023.

In terms of condition, the Middle East & Africa hyperpigmentation disorder treatment market is segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held the largest share of the Middle East & Africa hyperpigmentation disorder treatment market share in 2023.

By end user, the Middle East & Africa hyperpigmentation disorder treatment market is hospitals, dermatology centers, and others. The hospital segment held the largest share of the Middle East & Africa hyperpigmentation disorder treatment market share in 2023.

Based on country, the Middle East & Africa hyperpigmentation disorder treatment market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. The Rest of Middle East & Africa segment held the largest share of Middle East & Africa hyperpigmentation disorder treatment market in 2023.

AbbVie Inc, Bayer AG, Galderma SA, L'OREAL S.A., Lutronic Co Ltd, Obagi Cosmeceuticals LLC, and Pierre Fabre SA are some of the leading companies operating in the Middle East & Africa hyperpigmentation disorder treatment market.

Product Code: BMIRE00031385

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Middle East & Africa Hyperpigmentation Disorder Treatment Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rise in Prevalence of Melasma
- 4.1.2 Increasing Number of Hyperpigmentation Disorder Awareness Programs
4.2 Market Restraints
- 4.2.1 High Cost of Treatments
4.3 Market Opportunities
- 4.3.1 Strategic Initiatives by Market Players
4.4 Future Trends
- 4.4.1 Use of Ablative Lasers
- 4.4.2 Novel Products Based on PATH-3 Technology
4.5 Impact of Drivers and Restraints:

5. Hyperpigmentation Disorder Treatment Market - Middle East & Africa Analysis

5.1 Middle East & Africa Hyperpigmentation Disorder Treatment Market Revenue (US$ Million), 2020-2030

6. Middle East & Africa Hyperpigmentation Disorder Treatment Market Analysis - by Treatment Type

6.1 Cosmeceutical
- 6.1.1 Overview
- 6.1.2 Cosmeceutical: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Light or Laser Therapy
- 6.2.1 Overview
- 6.2.2 Light or Laser Therapy: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Microdermabrasion
- 6.3.1 Overview
- 6.3.2 Microdermabrasion: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Chemical Peels
- 6.4.1 Overview
- 6.4.2 Chemical Peels: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Cryotherapy
- 6.5.1 Overview
- 6.5.2 Cryotherapy: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. Middle East & Africa Hyperpigmentation Disorder Treatment Market Analysis - by Condition

7.1 Melasma
- 7.1.1 Overview
- 7.1.2 Melasma: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Solar Lentigines
- 7.2.1 Overview
- 7.2.2 Solar Lentigines: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Post-inflammatory Hyperpigmentation
- 7.3.1 Overview
- 7.3.2 Post-inflammatory Hyperpigmentation: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Hyperpigmentation Disorder Treatment Market Analysis - by End User

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Hospitals: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.2 Dermatology Centers
- 8.2.1 Overview
- 8.2.2 Dermatology Centers: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Hyperpigmentation Disorder Treatment Market - Country Analysis

9.1 Middle East & Africa Hyperpigmentation Disorder Treatment Market Overview
- 9.1.1 Middle East & Africa: Hyperpigmentation Disorder Treatment Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 Middle East & Africa Hyperpigmentation Disorder Treatment Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 Saudi Arabia
  - 9.1.1.3 Saudi Arabia: Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 Saudi Arabia: Hyperpigmentation Disorder Treatment Market Breakdown, by Treatment Type
    - 9.1.1.3.2 Saudi Arabia: Hyperpigmentation Disorder Treatment Market Breakdown, by Condition
    - 9.1.1.3.3 Saudi Arabia: Hyperpigmentation Disorder Treatment Market Breakdown, by End User
  - 9.1.1.4 South Africa
  - 9.1.1.5 South Africa: Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.1 South Africa: Hyperpigmentation Disorder Treatment Market Breakdown, by Treatment Type
    - 9.1.1.5.2 South Africa: Hyperpigmentation Disorder Treatment Market Breakdown, by Condition
    - 9.1.1.5.3 South Africa: Hyperpigmentation Disorder Treatment Market Breakdown, by End User
  - 9.1.1.6 UAE
  - 9.1.1.7 UAE: Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.7.1 UAE: Hyperpigmentation Disorder Treatment Market Breakdown, by Treatment Type
    - 9.1.1.7.2 UAE: Hyperpigmentation Disorder Treatment Market Breakdown, by Condition
    - 9.1.1.7.3 UAE: Hyperpigmentation Disorder Treatment Market Breakdown, by End User
  - 9.1.1.8 Rest of Middle East & Africa
  - 9.1.1.9 Rest of Middle East & Africa: Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.9.1 Rest of Middle East & Africa: Hyperpigmentation Disorder Treatment Market Breakdown, by Treatment Type
    - 9.1.1.9.2 Rest of Middle East & Africa: Hyperpigmentation Disorder Treatment Market Breakdown, by Condition
    - 9.1.1.9.3 Rest of Middle East & Africa: Hyperpigmentation Disorder Treatment Market Breakdown, by End User

10. Hyperpigmentation Disorder Treatment Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in Hyperpigmentation Disorder Treatment Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 AbbVie Inc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Galderma SA
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Obagi Cosmeceuticals LLC
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Bayer AG
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Lutronic Co Ltd
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 L'OREAL S.A.
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Pierre Fabre SA
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms